NRIX Stock Analysis: Nurix Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.479m USD | 12M Return: 97.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 54.2M
Qual. Beats: 0
Rev. Trend: 31.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule and antibody therapies for cancer, inflammatory conditions, and other diseases. Its pipeline includes NX-5948 and NX-2127, orally bioavailable BTK degraders in Phase 2 and Phase 1a/1b trials respectively for relapsed or refractory B-cell malignancies, as well as NX-1607, a CBL-B inhibitor in Phase 1a/1b development for immuno-oncology indications. The company is also advancing NX-0479/GS-6791, an IRAK4 degrader for rheumatoid arthritis and other inflammatory diseases.
Nurixs approach is built around targeted protein degradation, a therapeutic modality that harnesses the bodys natural protein disposal machinery to eliminate disease-driving proteins, rather than merely inhibiting their function like conventional small molecules. As a pre-commercial biotechnology firm, it relies on strategic partnerships-co-development and co-commercialization agreements with Gilead Sciences, Sanofi, and Pfizer-to support its R&D pipeline and share development risk.
The company was founded in 2009, originally as Nurix Inc., and was renamed Nurix Therapeutics, Inc. in October 2018. It is headquartered in Brisbane, California, and trades on the NASDAQ under the ticker NRIX within the GICS Biotechnology sub-industry.
- NX-5948 Phase 2 data readout in B-cell malignancies
- Milestone payments from Gilead Sanofi Pfizer partnerships
- Cash runway and capital allocation for pipeline development
| Net Income: -295.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA -9.96 > 1.0 |
| NWC/Revenue: 643.9% < 20% (prev 839.7%; Δ -195.8% < -1%) |
| CFO/TA -0.41 > 3% & CFO -260.3m > Net Income -295.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.1m) vs 12m ago 31.73% < -2% |
| Gross Margin: -139.4% > 18% (prev -327.7%; Δ 188.3% > 0.5%) |
| Asset Turnover: 11.47% > 50% (prev 9.17%; Δ 2.30% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 554.4m - Total Current Liabilities 92.2m) / Total Assets 636.1m |
| B: -1.71 (Retained Earnings -1.09b / Total Assets 636.1m) |
| C: -0.47 (EBIT TTM -294.5m / Avg Total Assets 625.6m) |
| D: 3.10 (Book Value of Equity 480.9m / Total Liabilities 155.2m) |
| Altman-Z'' = -0.73 = B |
| DSRI: 0.21 (Receivables 2.40m/9.10m, Revenue 71.8m/56.4m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.24 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.27 (Revenue 71.8m / 56.4m) |
| TATA: -0.06 (NI -295.3m - CFO -260.3m) / TA 636.1m) |
| Beneish M = -3.35 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 24.40 with a total of 1,239,725 shares traded. Over the past week, the price has changed by +2.31%, over one month by +56.01%, over three months by +49.24% and over the past year by +97.41%.
Current recommended Stop Loss: 22.80 (which is 6.6% or 1.2 ATR below the current price).
Nurix Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy NRIX.
- StrongBuy: 10
- Buy: 6
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.4 | 28.9% |
P/S = 34.5315
P/B = 5.1542
Revenue TTM = 71.8m USD
EBIT TTM = -294.5m USD
EBITDA TTM = -274.2m USD
Long Term Debt = 55.5m USD (estimated: total debt 58.7m - short term 3.20m)
Short Term Debt = 3.20m USD (from shortTermDebt, last quarter)
Debt = 58.7m USD (from shortLongTermDebtTotal, last quarter) (leases 58.7m already included)
Net Debt = -482.1m USD (calculated: Debt 58.7m - CCE 540.7m)
Enterprise Value = 2.00b USD (2.48b + Debt 58.7m - CCE 540.7m)
Interest Coverage Ratio = unknown (Ebit TTM -294.5m / Interest Expense TTM 0.0)
EV/FCF = -7.34x (Enterprise Value 2.00b / FCF TTM -271.9m)
FCF Yield = -13.62% (FCF TTM -271.9m / Enterprise Value 2.00b)
FCF Margin = -378.7% (FCF TTM -271.9m / Revenue TTM 71.8m)
Net Margin = -411.4% (Net Income TTM -295.3m / Revenue TTM 71.8m)
Gross Margin = -139.4% ((Revenue TTM 71.8m - Cost of Revenue TTM 171.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev 65.89%)
Tobins Q-Ratio = 3.14 (Enterprise Value 2.00b / Total Assets 636.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 58.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -232.7m (EBIT -294.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.01 (Total Current Assets 554.4m / Total Current Liabilities 92.2m)
Debt / Equity = 0.12 (Debt 58.7m / totalStockholderEquity, last quarter 480.9m)
Debt / EBITDA = 1.76 (negative EBITDA) (Net Debt -482.1m / EBITDA -274.2m)
Debt / FCF = 1.77 (negative FCF - burning cash) (Net Debt -482.1m / FCF TTM -271.9m)
Total Stockholder Equity = 459.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.20% (Net Income -295.3m / Total Assets 636.1m)
RoE = -64.21% (Net Income TTM -295.3m / Total Stockholder Equity 459.9m)
RoCE = -57.15% (EBIT -294.5m / Capital Employed (Equity 459.9m + L.T.Debt 55.5m))
RoIC = -42.81% (negative operating profit) (NOPAT -232.7m / Invested Capital 543.5m)
WACC = 10.35% (E(2.48b)/V(2.54b) * Re(10.60%) + D(58.7m)/V(2.54b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 36.48%
[DCF] Fair Price = unknown (Cash Flow -271.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: 31.06 | Revenue CAGR: 6.22% | SUE: -0.71 | # QB: 0
EPS current Quarter (2026-05-31): EPS=-0.72 | Chg30d=-0.25% | Revisions=+0% | Analysts=14
EPS next Quarter (2026-08-31): EPS=-0.24 | Chg30d=+67.88% | Revisions=+50% | Analysts=14
EPS current Year (2026-11-30): EPS=-2.35 | Chg30d=+20.14% | Revisions=+29% | GrowthEPS=+22.8% | GrowthRev=+69.6%
EPS next Year (2027-11-30): EPS=-2.67 | Chg30d=+6.75% | Revisions=+50% | GrowthEPS=-13.5% | GrowthRev=-42.7%
[Analyst] Revisions Ratio: +53% (up=10, down=2)